Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy
Monday, May 19, 2025 1 min read
Key Takeaway: The article discusses the use of an alloimmune defense receptor combined with the genetic ablation of the adhesion ligand CD58. This approach aims to enhance the functional persistence of allogeneic cell therapies without the need for conditioning chemotherapy. The focus is on improving therapeutic outcomes in cell therapy applications.
Price reaction · baseline $1.07 (2025-05-16 close) · hit pre-market · 3 other FATE headline(s) in the window, move may be shared
day 0 close
+14%
day 1 · peak
+16.8%
day 3
+12.1%
Market Sentiment Analysis
Full Press Release Details
• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.